Breaking News

Penn Pharma Marks Safety Milestone

By Kristin Brooks | January 24, 2014

Gwent facility operates three years without incident

Penn Pharma has reached a safety milestone, operating for three years without experiencing a reportable accident at its facility in Gwent, South Wales. The new contained manufacturing facility opened in September 2013, and along with the original facility, both been operating safely for 1.75 million hours with a staff of 300.
 
Penn Pharma chief operating officer Mark Dean-Netscher said, “With a background £18 million expansion program and significant construction activity on site, this is a fantastic achievement on our continued journey for Operational Excellence in Penn. We have superb engagement from all of our staff with a very active ‘near miss’ system and safety-focused culture in place. Our safety record ranks with the best in the pharmaceutical sector. It shows that Penn applies the same importance to the safety of our staff, as we do to the safety of the medicines we supply to patients worldwide.”
 
Penn Pharma provides integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry. The company recently retained its accreditation for ISO14001 standard for environmental management, following a two-day audit by its certification body.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer